Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Pulmocide pulls ph. 3 antifungal trial over mortality rate
The British biotech is now performing a thorough review of the trial data to determine the future of its opelconazole program.
Darren Incorvaia
Jan 7, 2026 10:57am
Neuro biotech Nido closes after 5 years
Jan 2, 2026 10:24am
Ultragenyx plans cost-cutting push after flunking phase 3 trials
Jan 2, 2026 5:37am
Biohaven flunks depression trial, adding to CNS release concerns
Jan 2, 2026 4:48am
AstraZeneca's ph. 3 cancer fail is latest blow to ATR inhibitors
Dec 22, 2025 4:35am
Galapagos' last immunology asset posts mixed results
Dec 19, 2025 6:05am
